RxDoctor Payments DataLook up a doctor →

Diane Gronski, MD

Endocrinology, Diabetes & Metabolism · Glendale, AZNPI 1689624629

Payments from drug & device makers

$98,320in general payments, 2019–2025

Across 947 payments — averaging $103.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$37K
  • Sanofi-aventis U.S. LLC$21K
  • Bayer$13K
  • Abbott$11K
  • Novo Nordisk$5K
  • Amgen$3K
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$2,3202%
  • Speaking & faculty fees$74,53476%
  • Travel & lodging$9121%
  • Food & beverage$20,39121%
  • Education$1640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)111$36,792
Sanofi-aventis U.S. LLC81$21,364
Bayer41$13,492
Abbott27$10,542
Novo Nordisk132$4,529
Amgen(2 entities)107$2,535
AbbVie(2 entities)55$1,350
Medtronic(3 entities)30$899
Lilly USA, LLC62$630
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC27$487
Radius Health, Inc.25$465
Edwards Lifesciences6$371
Corcept Therapeutics15$350
Boehringer Ingelheim19$302
Nestle Healthcare Nutrition Inc.14$280
Insulet Corporation8$228
Recordati_rare_diseases_inc.11$223
Amarin Pharma, Inc.11$223
Boston Scientific6$206
Echosens North America, Inc.1$198
Daiichi Sankyo Inc.12$196
Merck11$161
Biohaven Pharmaceutical Holding Company Ltd.8$160
Biohaven Pharmaceuticals, Inc.9$159
GRT US Holding, Inc.1$109
Takeda Pharmaceuticals U.S.A., Inc.6$109
Aimmune Therapeutics, Inc.6$102
Teva Pharmaceuticals USA, Inc.4$96
Kowa Pharmaceuticals America, Inc.7$96
Hologic Sales And Service, LLC5$91
Dexcom, Inc.5$88
Esperion Therapeutics, Inc.6$84
GSK5$83
Kyowa Kirin, Inc.3$81
Exact Sciences5$80
Johnson & Johnson(2 entities)6$77
Pfizer4$70
Chiesi USA, Inc.3$64
Lucid Diagnostics Inc.4$58
Currax Pharmaceuticals LLC4$56
Topcon Healthcare Solutions, Inc.1$55
Xeris Pharmaceuticals, Inc.3$54
Cleerly, Inc.1$53
Amryt Pharma Holdings Ltd2$49
Otsuka America Pharmaceutical, Inc.2$39
Idorsia Pharmaceuticals US Inc2$37
Cequr Corporation3$37
Ultragenyx Pharmaceutical Inc.2$34
Eisai Inc.2$29
Sandoz1$27
Nalpropion Pharmaceuticals LLC2$27
Ascendis Pharma Endocrinology Inc1$25
Inspire Medical Systems, Inc.1$25
Mayne Pharma Commercial LLC1$24
Biotronik NRO, Inc.1$22
Sun Pharmaceutical Industries Inc.1$21
Lifescan, Inc.1$21
Intuitive Surgical1$20
Sumitomo Pharma America, Inc.1$19
Impel Pharmaceuticals Inc.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,320 in reported general payments places this provider in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$167,227
Medicare patients
639
Services billed
2,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide480$874,416
FarxigaDapagliflozin Propanediol397$415,468
MounjaroTirzepatide214$290,328
JardianceEmpagliflozin201$265,235
Soliqua 100-33Insulin Glargine/Lixisenatide226$226,655
RybelsusSemaglutide140$204,744
TrulicityDulaglutide116$179,624
Tresiba Flextouch U-200Insulin Degludec64$101,596
Tresiba Flextouch U-100Insulin Degludec150$88,269
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog48$67,083
JanuviaSitagliptin Phosphate61$66,336
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog103$66,288
Fiasp FlextouchInsulin Aspart (Niacinamide)48$60,676
TradjentaLinagliptin38$44,826
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$39,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$4,529$1,089,505668 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$630$490,366387 claims
AstraZenecaFarxiga$36,792$415,468397 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$302$329,036250 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$21,364$235,898256 claims
MerckJanuvia$161$66,33661 claims
AbbVieSynthroid$1,350$21,464252 claims
PfizerGenotropin$70$14,43917 claims
Johnson & JohnsonInvokana$77$12,43216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →